Research output per year
Research output per year
Personal profile
Research interests
I am interested in understanding how epigenetic changes contribute to tumorigenesis, disease progression and the development of therapy resistance, and how we can exploit these aberrations to engineer novel therapeutic approaches. In the lab, we utilize experimental, computational, and high-throughput technologies to study and modulate the epigenetic changes in cancer with the goal of (1) identifying the epigenetic drivers of cancer development and progression (2) identifying epigenetic alterations and the mechanisms underlying targeted and immuno-therapy resistance (3) exploit novel epigenetic targets and develop therapeutic strategies.
External positions
Assistant Professor of Cancer Biology in Surgery, Weill Cornell Medical College
Jun 1 2023 → …
Research Area Keywords
- Cancer
Free-text keywords
- Epigenomics
- Transcriptional regulation
- Immunotherapy
- therapy resistance
Fingerprint
Dive into the research topics where Mahinur Mattohti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer
Orouji, E., Raman, A. T., Singh, A. K., Sorokin, A., Arslan, E., Ghosh, A. K., Schulz, J., Terranova, C., Jiang, S., Tang, M., Maitituoheti, M., Callahan, S. C., Barrodia, P., Tomczak, K., Jiang, Y., Jiang, Z., Davis, J. S., Ghosh, S., Lee, H. M., Reyes-Uribe, L., & 9 others, May 1 2022, In: Gut. 71, 5, p. 938-949 12 p.Research output: Contribution to journal › Article › peer-review
20 Scopus citations -
The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma
Lamhamedi-Cherradi, S. E., Maitituoheti, M., Menegaz, B. A., Krishnan, S., Vetter, A. M., Camacho, P., Wu, C. C., Beird, H. C., Porter, R. W., Ingram, D. R., Ramamoorthy, V., Mohiuddin, S., McCall, D., Truong, D. D., Cuglievan, B., Futreal, P. A., Velasco, A. R., Anvar, N. E., Utama, B., Titus, M., & 10 others, Dec 2022, In: Nature Communications. 13, 1, 3057.Research output: Contribution to journal › Article › peer-review
Open Access11 Scopus citations -
KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma
Murugesan, N. & Maitituoheti, M., 2021, In: Molecular and Cellular Oncology. 8, 5, 1984827.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy
Terranova, C. J., Tang, M., Maitituoheti, M., Raman, A. T., Ghosh, A. K., Schulz, J., Amin, S. B., Orouji, E., Tomczak, K., Sarkar, S., Oba, J., Creasy, C., Wu, C. J., Khan, S., Lazcano, R., Wani, K., Singh, A., Barrodia, P., Zhao, D., Chen, K., & 6 others, Jul 20 2021, In: Cell Reports. 36, 3, 109410.Research output: Contribution to journal › Article › peer-review
Open Access12 Scopus citations -
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma
Maitituoheti, M., Keung, E. Z., Tang, M., Yan, L., Alam, H., Han, G., Singh, A. K., Raman, A. T., Terranova, C., Sarkar, S., Orouji, E., Amin, S. B., Sharma, S., Williams, M., Samant, N. S., Dhamdhere, M., Zheng, N., Shah, T., Shah, A., Axelrad, J. B., & 12 others, Oct 20 2020, In: Cell Reports. 33, 3, 108293.Research output: Contribution to journal › Article › peer-review
Open Access31 Scopus citations